ARTICLES

FDA Approves Takeda’s ORZEYFUL for Narcolepsy Type 1
Industry News Narcolepsy Pharmacological Sleep Disorders

U.S. FDA Approves Takeda’s ORZEYFUL (oveporexton), the First and Only Orexin Agonist for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. […]

AI Identifies Previously Unrecognized Health Insights in Routine Sleep Studies
Artificial Intelligence Clinical Insights & Research Technology

AI Identifies Previously Unrecognized Health Insights in Routine Sleep Studies

A novel AI model can use information collected during routine sleep studies to identify patients’ long-term health risks, according to a new study published in Nature Communications. Developed by a multidisciplinary research team, the model uncovered hidden sleep patterns linked to risks including heart disease, cognitive decline and death. The […]

New Study Uses Sleep Monitoring and AI to Detect Alzheimer's
Artificial Intelligence Clinical Insights & Research Technology

New Study Uses Sleep Monitoring and AI to Detect Alzheimer’s

Researchers from Universidad Carlos III de Madrid (UC3M) and Hospital Universitario Severo Ochoa in Leganés, part of the public health network of the Comunidad de Madrid, have developed a methodology that uses artificial intelligence (AI) to analyze brain electrical activity during sleep and facilitate the early diagnosis of Alzheimer’s. The […]